Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 451 - 500 out of 121,039

Document Document Title
WO/2016/184121A1
A new compound (as shown in formula I) and salts thereof, which are proved to be used for treating and preventing cerebral ischemic diseases and improving sleep by experiments. When R=H, salts are respectively generated by the compound t...  
WO/2016/185443A1
The present invention relates to a combination comprising (a) RAD001, or a pharmaceutically acceptable salt thereof, and (b) BEZ235, or pharmaceutically acceptable salt thereof, for simultaneous, separate or sequential use for enhancemen...  
WO/2016/186967A1
The present disclosure provides indoleamine 2,3 -dioxygenase 1 (IDO1) inhibitors of Formula I: or pharmaceutically acceptable salts thereof, in which X, L, n, m, R1, R2a, R2b, Rn, Rm, and R1 are as defined herein, as well as pharmaceutic...  
WO/2016/186184A1
The objective of the present invention is to provide: a crystal having high purity and excellent properties (such as stability and solubility) of a highly safe compound with few side effects, said compound having μ-opioid receptor antag...  
WO/2016/185160A1
A first aspect of the- invention relates to a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, (Formula (I)) wherein: R1 is (CH2)mNR11R12;R2 is selected from H, halo, OR13, ΝΗR13, alkyl, alkenyl and alky...  
WO/2016/184310A1
The present invention relates to 4-methyl-1H-diaryl pyrazole derivatives, and specifically relates to the compounds represented by formula (I) and stereoisomers, solvates or pharmaceutically acceptable salts thereof. The present inventio...  
WO/2016/186204A1
Provided are a micelle for nucleic acid delivery using a temperature-sensitive polymer, and a method for producing the micelle. For example, provided is a polyion complex comprising a temperature-sensitive copolymer and a nucleic acid, w...  
WO/2016/185032A1
The present disclosure relates to certain novel compounds of Formula (I) and to their utility in modulation of levels of monoamines, dopamine, norepinephrine and serotonin, in cerebral cortical areas of the mammalian brain, and more spec...  
WO/2016/187595A3
An oral modified release pharmaceutical composition of methylergonovine suitable for oral once daily administration is provided. The composition includes at least about 0.6 mg dose of methylergonovine or a pharmaceutically acceptable sal...  
WO/2016/187558A3
A method of improving brain function in a hypothermic patient is provided. The method comprises administering to the patient an amount of a fibroblast growth factor 21 (FGF21) effective to increase RNA binding motif 3 (RBM3) production i...  
WO/2016/186772A2
Provided herein are compositions, methods, kits, and viral particles for treating a disease or disorder associated with a deep intronic mutation using an engineered, non- naturally occurring Clustered Regularly Interspaced Short Palindro...  
WO/2016/185423A1
Disclosed are compounds having the formula: (I) wherein R1, R2, and R3 are as defined herein, and methods of making and using the same.  
WO/2016/183741A1
The present invention is directed to pyrimidinone amide compounds which may be useful as therapeutic agents for the treatment of central nervous system and/or peripheral disorders associated with phosphodiesterase 2 (PDE2). The present i...  
WO/2016/184381A1
Provided is a use of dextrorotatory oxiracetam in the preparation of a drug for preventing or treating epilepsy. An experimental result shows that the dextrorotatory oxiracetam has an obvious effect in the treatment of generalized epilep...  
WO/2016/187228A1
Neonatal seizure is different from adult seizure, and many antiepileptic drugs that are effective in adults often fail to treat neonatal seizure. Gluconic acid, a natural organic acid enriched in fruits and honey, is shown herein to pote...  
WO/2016/184427A1
Disclosed are a mesenchymal stem cell hypoxically cultured and the use thereof, wherein the stem cell can relieve or treat inflammatory diseases, thereby producing an insulin-like growth factor-2 which plays a central role in the treatme...  
WO/2016/183578A1
A new class of quinoline compounds is useful for the detection and treatment of Alzheimer's disease and other neurodegenerative diseases such as amyloidoses and tauopathies. The compounds can be synthesized in radiolabeled form for use a...  
WO/2016/179645A1
The present disclosure relates to 4H-pyran compounds of formula (I) and their use in therapy, to compositions and agents comprising said compounds, to methods of treatment using said compounds, and their use in the manufacture of medicam...  
WO/2016/182988A1
In certain embodiments the present invention provides methods useful in the treatment of glioma, such as glioblastoma, such methods comprising administering to a subject in need thereof a CSF-IR inhibitor together with one or more additi...  
WO/2016/183252A1
The present disclosure provides for methods of treating a neurodegenerative condition, as well as methods for assessing the risk of developing a neurodegenerative condition, and assessing treatment efficacy in subjects who are carriers o...  
WO/2016/181894A1
The present invention provides a compound which has an excellent TLR4 signaling inhibitory effect and is useful as a prophylactic or therapeutic agent for diseases such as autoimmune diseases and/or inflammatory diseases, chemotherapy-in...  
WO/2016/182862A1
Formulations comprising recombinant human tripeptidyl peptidase- 1 (rhTPPl) for intrathecal, intracerebroventricular, or intraocular administration, and kits comprising the same, are disclosed. Methods of using rhTPPl in the prevention a...  
WO/2016/180751A1
The invention provides novel compounds having the general formula (I) wherein R1, R2, R3, R4, R5, R6, R7, R8 and R9 are as described herein, compositions including the compounds and methods of using the compounds.  
WO/2016/183425A1
The invention relates to a micro-encapsulation system for immobilizing mesenchymal stem cells (MSCs), methods for delivery of encapsulated MSCs into the central nervous system, and use of the encapsulated cells as cellular transplantatio...  
WO/2016/181945A1
The purpose of the present invention is to provide a novel composition and solvent for facilitating the production of a brain-derived neurotrophic factor (BDNF) and a method for facilitating the production of BDNF. According to the prese...  
WO/2016/180870A1
The present invention provides vortioxetine pyroglutamate salt and pharmaceutical compositions comprising said salt.  
WO/2016/180981A1
The present invention provides 2-Methyl-amino-3-[(4-fluorophenyl) carbonyl] indolizine-1-carboxamide of formula (I) or a pharmaceutically acceptable salt thereof and its therapeutic uses in the treatment of neurodegenerative disorders, i...  
WO/2016/180472A1
A compound of formula (I) or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the compound. The compound is useful in therapy, for the treatment of disorders mediated by HDAC6, such as autoimmune di...  
WO/2016/182036A1
The present invention provides compounds having a Toll-like receptor 4 (TLR4) signaling inhibitory action useful as preventive and therapeutic drugs of inflammatory disease and/or central nervous system disease or diseases such as chemot...  
WO/2016/180247A1
The present invention relates to a bicyclic compound used as an Lp-PLA2 inhibitor, a preparation method and pharmaceutical use thereof, and a pharmaceutical composition containing the compound. The structure of the bicyclic compound is s...  
WO/2016/180879A1
The present disclosure relates to a dopamine stabilizing agent and an anti-depressive agent for use in the treatment of disorders characterized by debilitating fatigue, such as myalgic encephalomyelitis (ME)/Chronic fatigue syndrome (CFS...  
WO/2016/183244A1
This disclosure is directed to a method of treating dependency on an opioid drug, including acute and post-acute withdrawal symptoms, comprising treating an opioid-dependent patient with noribogaine, noribogaine derivative, or pharmaceut...  
WO/2016/182840A1
The present invention relates to compounds and their use as ligands for mu opioid receptors. Also included are methods for preparing the compounds and pharmaceutical compositions containing the compounds. In one or more embodiments of th...  
WO/2016/179566A1
The present application relates to new uses of 5-HT6 receptor antagonists, specifically high doses of 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline, and to the combination of 5-HT6 receptor antagonists, specifically 3-phenylsulfonyl-8-pip...  
WO/2016/179217A1
Compositions and methods involving the co- application of a thrombolytic drug and a metal ion chelator are described.  
WO/2016/179481A1
Methods and compositions for treating a lysosomal movement associated disease in an animal, in which the position of lysosomes can influence disease progression, comprising administering an effective amount of a first lysosome migration ...  
WO/2016/177840A1
The present invention relates to a combination therapy comprising the use of riboflavin and oxaloacetate. Specifically, it is directed to new compositions, pharmaceutical compositions, kits of parts and methods for treating ischemic stro...  
WO/2016/177340A1
The present invention relates to bicyclic substituted benzene sulfonamide derivative, and the preparation method and pharmaceutical use thereof. In particular, disclosed in the present invention are the compound of formula (I) or a pharm...  
WO/2016/179398A1
Isoform-selective lysine deacetylase inhibitors are described. Inhibitors of the lysine deacetylase enzyme are useful as antitumor drugs and for treating addiction, asthma, cardio-vascular disease, immunosuppression, neurodegenerative di...  
WO/2016/179497A1
The present invention is directed, in part, to the treatment of a subject having a neurodegenerative disorder, such as Parkinson's disease (PD), by providing glucocerebrosidase enzyme. The enzyme may be provided, e.g., through gene thera...  
WO/2016/179252A1
The present invention provides an orally-administrable, pharmaceutical formulation comprising: a plurality of pellets, wherein: the pellets comprise a core, a sustained release coating, and an enteric coating; and the core comprises an a...  
WO/2016/179569A1
The present application relates to new uses of 5-HT6 receptor antagonists, specifically 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline or pharmaceutically acceptable salts, hydrates, solvates, or polymorphs, thereof, and to the combination...  
WO/2016/173710A1
The present invention relates to compounds having pharmacological activity towards the sigma (σ) receptor, and more particularly to spiro-isoquinoline-3,4'-piperidine compounds having this pharmacological activity, to processes of prepa...  
WO/2016/176177A1
Provided in some embodiments are compounds herein. Also provided in some embodiments are methods for weight management, inducing satiety, and decreasing food intake, and for preventing and treating obesity, antipsychotic-induced weight g...  
WO/2016/173425A1
This present invention relates to a glucopyranosyl derivative as sodium dependent glucose cotransporters (SGLTs) inhibitor, preparation processes thereof, and pharmaceutical uses thereof, pharmaceutical compositions containing the compou...  
WO/2016/176687A3
Disclosed herein are methods of purifying growth cones from specific projections in the brain comprising a combination of in vivo labeling, subcellular fractionation, and fluorescent small particle sorting. The methods disclosed herein e...  
WO/2016/176457A1
Provided herein are compounds of Formula (I), and pharmaceutically acceptable salts, N-oxides, or solvates thereof, [Formula should be inserted here] Also provided herein are pharmaceutical compositions, comprising compounds of Formula (...  
WO/2016/175240A1
Provided is an external agent for treating hyperhidrosis, said external agent comprising water, an anticholinergic and one or more salts selected from the group consisting of a lactate, tartrate, acetate and phosphate. This external agen...  
WO/2016/174188A1
The present invention provides imidazopyrazinones as PDE1 inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders.  
WO/2016/172855A1
Provided is a high performance liquid chromatography method for polypeptide mixtures. Specifically, the method comprises the following steps of (1) formulating a Glatiramer acetate solution to be tested; (2) subjecting the sample to be t...  

Matches 451 - 500 out of 121,039